Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Non-Current Assets of $20.0 million for Q1 2026, down 10.47% year-over-year from $22.3 million in Q1 2025, and up 4.42% quarter-over-quarter from $19.1 million in Q4 2025.
Scholar Rock Holding (SRRK) Non-Current Assets (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non-Current Assets history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 10.47% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $81.0 million (down 18.98% YoY), while the FY2025 annual figure was $19.1 million, down 19.5% from the prior year.
- Non-Current Assets for Q1 2026 stood at $20.0 million, up from $19.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $37.4 million in Q1 2022, with the low at $19.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $23.8 million (2024), against an average of $25.5 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets sank 32.02% in 2023, then advanced 17.92% in 2024.
- Scholar Rock Holding's Non-Current Assets stood at $30.1 million in 2022, then dropped by 24.23% to $22.8 million in 2023, then increased by 4.01% to $23.8 million in 2024, then decreased by 19.5% to $19.1 million in 2025, then rose by 4.42% to $20.0 million in 2026.
- Business Quant data shows SRRK's Non-Current Assets at $20.0 million in Q1 2026, $19.1 million in Q4 2025, and $21.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 16.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.36 Mn |
| Mar 31, 2026 | 19.97 Mn |
| Dec 31, 2025 | 19.13 Mn |
| Sep 30, 2025 | 21.01 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 22.31 Mn |
| Dec 31, 2024 | 23.76 Mn |
| Sep 30, 2024 | 26.21 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 20.35 Mn |
| Dec 31, 2023 | 22.84 Mn |
| Sep 30, 2023 | 22.22 Mn |
| Jun 30, 2023 | 25.09 Mn |
| Mar 31, 2023 | 27.56 Mn |
| Dec 31, 2022 | 30.14 Mn |
| Sep 30, 2022 | 32.69 Mn |
| Jun 30, 2022 | 34.99 Mn |
| Mar 31, 2022 | 37.39 Mn |
| Dec 31, 2021 | 39.13 Mn |
| Sep 30, 2021 | 40.23 Mn |